Opinions on Biotechnology | Labiotech.eu

Unlocking the power of mRNA technology

External Contributor — Tue, 11 Jul 2023 07:57:29 +0000

By Yochi Slonim, CEO and co-founder of Anima Biotech mRNA technology has gained widespread recognition due to its role in the development of vaccines, such as those used against COVID-19; however, the scope of mRNA extends far beyond vaccines, offering a range of applications for addressing different conditions. Vaccines represent a notable application of mRNA […]

The post Unlocking the power of mRNA technology appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Five innovations to take RNA vaccines to the next level

External Contributor — Mon, 10 Jul 2023 09:07:59 +0000

By Venkata Indurthi, PhD, chief scientific officer, Aldevron During the COVID-19 pandemic, the world turned to a previously unused vaccine technology to rapidly develop desperately needed vaccines, providing immunity to millions worldwide. These new vaccines made use of the body’s natural translational machinery, which turns mRNA encoding the SARS-Cov2 spike protein into an antigen that […]

The post Five innovations to take RNA vaccines to the next level appeared first on Labiotech.eu.

Virus tracking could be key to kidney transplant patients’ drug choices

External Contributor — Fri, 30 Jun 2023 08:32:49 +0000

By Dr Gregor Bond More than 15,000 Europeans undergo kidney transplants on average each year, and while medical advances have helped many recipients enjoy healthy lives, the risks of organ rejection and infection remain huge challenges. With each transplant, success depends on using carefully balanced doses of immuno-suppressive drugs to reduce the risk of infection […]

The post Virus tracking could be key to kidney transplant patients’ drug choices appeared first on Labiotech.eu.

How will European Commission proposals on data exclusivity and the bolar exemption affect pharma companies?

External Contributor — Tue, 13 Jun 2023 07:16:25 +0000

By Andrew Sharples, co-head of EIP’s UK litigation team In April, the European Commission published proposed legislation (specifically a new Regulation and a new Directive) aimed at reforming EU legislation in relation to pharmaceuticals. These proposals, if adopted, will affect pharmaceutical regulation in several ways. In relation to IP specifically, they will affect the periods […]

The post How will European Commission proposals on data exclusivity and the bolar exemption affect pharma companies? appeared first on Labiotech.eu.

Where is innovation needed in cell therapy?

External Contributor — Tue, 09 May 2023 14:35:00 +0000

By Dr Ryan Roberts, cell processing lead at Cellular Origins Despite the rapidly emerging innovations in the field of cell and gene therapy, bottlenecks in cell therapy manufacturing processes are preventing these transformative medicines from reaching patients. There are several broad challenges to the scalability and affordability of cell therapies, including a reliance on manual […]

The post Where is innovation needed in cell therapy? appeared first on Labiotech.eu.

Can mRNA vaccines tackle multiple diseases?

External Contributor — Wed, 26 Apr 2023 10:04:01 +0000

By Dr. Myriam Mendila, chief development officer of CureVac World Immunization Week is April 24-30, and it’s an important week to highlight the action needed and to promote the use of vaccines to protect people around the world, of all ages, against infectious diseases. World Immunization Week aims to promote the use of vaccines to […]

The post Can mRNA vaccines tackle multiple diseases? appeared first on Labiotech.eu.

How to address declining vaccination rates in older adults

External Contributor — Wed, 26 Apr 2023 09:14:00 +0000

By Philip Dormitzer, global head of vaccines research and development, GSK The vaccines landscape has changed greatly over the last few years in light of the COVID-19 pandemic. New technologies have been applied at scale, innovative vaccine programs rolled out, and supply chains rearranged to help tackle global health challenges. But, while innovation has improved […]

The post How to address declining vaccination rates in older adults appeared first on Labiotech.eu.

20 years ago today: how genetic sequencing is changing lives since the Human Genome Project

External Contributor — Fri, 14 Apr 2023 09:43:38 +0000

By Dr. Radoje Drmanac, CSO of MGI and Complete Genomics Today marks the 20th anniversary of the completion of the first human genome sequence, which was mapped out on April 14, 2003. Initially a targeted effort to understand the impact of radiation on human beings, the Human Genome Project (HGP) set in motion countless advancements […]

The post 20 years ago today: how genetic sequencing is changing lives since the Human Genome Project appeared first on Labiotech.eu.

PAN-TB regimens to address growing TB drug resistance

External Contributor — Fri, 24 Mar 2023 09:11:25 +0000

By Dr. Charles Wells, head of therapeutics development at Gates Medical Research Institute As nearly one-quarter of the world’s population is presumed to be infected with Mycobacterium tuberculosis bacteria and are at risk for developing active tuberculosis (TB), the disease represents a major public health challenge globally. As reported by the World Health Organization (WHO), […]

The post PAN-TB regimens to address growing TB drug resistance appeared first on Labiotech.eu.

Should pharma be listening to social media to drive drug development?

External Contributor — Wed, 08 Mar 2023 13:41:00 +0000

By Thierry Escudier, consultant and strategic leader at The Pistoia Alliance The move towards patient centricity is gathering momentum, and digital technology is playing a huge role in this shift. Decentralized clinical trials that employ mobile apps and wearable devices to monitor patients and make results gathering easier are a particularly successful example of how […]

The post Should pharma be listening to social media to drive drug development? appeared first on Labiotech.eu.

Life changing treatments for rare disease – a beacon of hope

External Contributor — Tue, 28 Feb 2023 10:52:04 +0000

By Sander Slootweg, managing partner, Forbion More than 300 million people around the globe are affected by a rare disease. This number does not even take into account the impact on these individuals’ support units that includes family, friends and caregivers. A rare disease is defined as a disease that affects no more than 1 […]

The post Life changing treatments for rare disease – a beacon of hope appeared first on Labiotech.eu.

How AI and ML can transform clinical research

External Contributor — Thu, 09 Feb 2023 10:48:34 +0000

By Gary Shorter, head of artificial intelligence at IQVIA Clinical trials are currently in an era of transformation through digitization, with much of the change being attributed to the integration of technologies such as natural language processing (NLP), artificial intelligence (AI), and machine learning (ML). Like many industries, health and life sciences are experiencing rapid […]

The post How AI and ML can transform clinical research appeared first on Labiotech.eu.

AI and experiments: new possibilities emerge in 2023

External Contributor — Fri, 03 Feb 2023 08:22:34 +0000

By Markus Gershater, co-founder and chief scientific officer, Synthace The buzz surrounding generative AI has reached fever pitch. It’s a technology so unique and fascinating that the breadth of possibility has done that rare thing of exciting both consumer and business imaginations at the same time. It’s not hard to see why. In the life […]

The post AI and experiments: new possibilities emerge in 2023 appeared first on Labiotech.eu.

How digital biomarker assays can harness the power of deep learning from clinical trials to the clinic

External Contributor — Thu, 02 Feb 2023 11:37:19 +0000

By Joe Oakley, MD, medical director of biomarker development, Paige Just as much of medicine has begun to undergo a digital transformation in the past decade, so has pathology. Now, biomarkers, which are indications of particular features of cancer and are essential to diagnosis and treatment, are beginning their own digital revolution. This is an […]

The post How digital biomarker assays can harness the power of deep learning from clinical trials to the clinic appeared first on Labiotech.eu.

How AI is reshaping cancer diagnosis and treatment

Jim Cornall — Wed, 01 Feb 2023 08:38:46 +0000

By Soheila Borhani, School of Biomedical Informatics, University of Texas Health Science Center Since its first documented case circa 3000 B.C., cancer has remained at the top of the list of most formidable diseases in human history, and continues to be a leading cause of death worldwide. In 2020, nearly 10 million people lost their […]

The post How AI is reshaping cancer diagnosis and treatment appeared first on Labiotech.eu.

Computational chemistry and cancer

External Contributor — Wed, 01 Feb 2023 07:08:00 +0000

by Martin Slater, Cresset Discovery Computational chemistry offers a fast and innovative approach to drug discovery and is especially powerful when used in combination with biological testing to provide a complete and reliable picture of a target system. This is perhaps no better illustrated than in Cresset Discovery’s project with University of South Australia, which […]

The post Computational chemistry and cancer appeared first on Labiotech.eu.

Innovation in life sciences requires collaboration and community

External Contributor — Wed, 18 Jan 2023 17:15:07 +0000

By Claudia Tripp and Katie Nelson, Kadans Science Partner Collaboration has underpinned some of the most impactful innovations of recent years. For example, the rapid development of the COVID vaccine was only made possible due to collaboration. Pfizer’s rapidly-established partnership with BioNTech delivered the first vaccine at lightning speed. Having established an ecosystem approach to […]

The post Innovation in life sciences requires collaboration and community appeared first on Labiotech.eu.

Artificial intelligence: a new era in rare genetic disease diagnosis

External Contributor — Mon, 12 Dec 2022 15:00:52 +0000

Despite the onset of the genomics era, rare disease diagnosis remains a challenge. Nostos Genomics’ co-founder, Rocío Acuña Hidalgo, and chief operating officer, Ansgar Lange, shed light on how artificial intelligence (AI) could fill in the gaps. It is estimated that 300 million people worldwide are affected by rare diseases and around 80% of these […]

The post Artificial intelligence: a new era in rare genetic disease diagnosis appeared first on Labiotech.eu.

Precision medicine research must lose its Eurocentricity

External Contributor — Tue, 25 Oct 2022 17:02:41 +0000

Precision medicine research relies on genetic testing at scale, but how do we reach more diverse patient populations and collect nationally representative samples? Patrick Short, CEO and co-founder of Sano Genetics, and Natasha Ratcliffe, director of community engagement and partnerships at Couch Health, explain how Eurocentricity is holding back genetics, and what can be done. […]

The post Precision medicine research must lose its Eurocentricity appeared first on Labiotech.eu.

Hiding in plain sight: how to solve bioscience’s software problem

External Contributor — Mon, 24 Oct 2022 07:15:22 +0000

Guy Levy-Yurista, CEO of the experiment platform developer Synthace, gives his take on what’s missing in increasingly software-dependent life sciences labs: a holistic mindset for improving experimental methods. There’s a major problem holding back progress in biotech, and more widely in the life sciences. It’s not an obvious one, but based on the conversations I […]

The post Hiding in plain sight: how to solve bioscience’s software problem appeared first on Labiotech.eu.